Search results for: 'biologicals forecast'

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020. The pharma E&L testing market is ...

The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generatio...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

According to the Centers for Medicare and Medicaid Services (CMS), value-based care (VBC) programs reward healthcare providers with incentive payments for the quality of care they provide Medicare patients. These programs are part of its larger CMS quality strategy to reform healthcare delivery and payment. Value-based programs support 3 aims: b...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...